I took a look at that a long while back. If I reme
Post# of 148163
(Total Views: 559)
Posted On: 01/01/2024 9:41:23 PM
I took a look at that a long while back. If I remember correctly it boosts a lot of inflammatory cytokines that leronlimab downregulates. Which is a sledgehammer approach to try and kill tumor cells that made me shake my head. You would think the boosting of pro-inflammatory chemokines could improve the killing of tumor cells but that would also increase the tumor's ability to hijack the immune system to protect itself.
They've failed at all trials and are trying to push it in a small subgroup that showed improvement.
I don't remember that from when I last looked at it so I went and took another look. Given that high PD-1/PD-L1 is a hallmark of tumor progression it seems like an astonishing thing to target.
That actually had me laughing. Who the hell are they trying to fool. In their trial low PD-L1 expressing patients survived longer than high PD-L1. Of course low PD-L1 patients survive longer it wouldn't be due to their drug but because they're low PD-L1.
Their stock trades ten times higher because they have much fewer shares. To look at how the market values the companies look at market cap. CEL-SCI - $135.948 million, Cytodyn - $181.575M. Of course valuation is based on actual value and perceived potential. For those who don't understand the science they may actually take CEL-SCI's claims on PD-L1 seriously and the valuation would be wrong.
How long ago was that? After their claim on PD-L1, Merck would have steered clear realizing they were full of crap.
They've failed at all trials and are trying to push it in a small subgroup that showed improvement.
Quote:
targets low PD-L1
I don't remember that from when I last looked at it so I went and took another look. Given that high PD-1/PD-L1 is a hallmark of tumor progression it seems like an astonishing thing to target.
Quote:
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors which most often show longer survival in a proportion of patients with a higher level of tumor cell PD-L1 expression
https://www.biospace.com/article/releases/cel...ck-cancer/
That actually had me laughing. Who the hell are they trying to fool. In their trial low PD-L1 expressing patients survived longer than high PD-L1. Of course low PD-L1 patients survive longer it wouldn't be due to their drug but because they're low PD-L1.
Quote:
trades at ten times our current value
Their stock trades ten times higher because they have much fewer shares. To look at how the market values the companies look at market cap. CEL-SCI - $135.948 million, Cytodyn - $181.575M. Of course valuation is based on actual value and perceived potential. For those who don't understand the science they may actually take CEL-SCI's claims on PD-L1 seriously and the valuation would be wrong.
Quote:
...they have had talks with Merck.
How long ago was that? After their claim on PD-L1, Merck would have steered clear realizing they were full of crap.
(11)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼